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Abstract. Hypoxia is a critical event in tumor progression
and angiogenesis. Hypoxia can be detected noninvasively by
a novel spectroscopic photoacoustic tomography technology
(SPAT) and this finding is supported by our molecular biology
investigation aimed to elucidate the etiopathogenesis of SPAT
detected hypoxia and angiogenesis. The present study provides
an integrated approach to define oxygen status (hypoxia) of
intracranial tumor xenografts using spectroscopic photoacoustic
tomography. Brain tumors can be identified based on their
distorted vascular architecture and oxygen saturation (SO2)
images. Noninvasive in vivo tumor oxygenation imaging using
SPAT is based on the spectroscopic absorption differences
between oxyhemoglobin (O2Hb) and deoxyhemoblobin (HHb).
Sprague-Dawley rats inoculated intracranially with ENU1564,
a carcinogen-induced rat mammary adenocarcinoma cell line,
were imaged with SPAT three weeks post inoculation. Proteins
important for tumor angiogenesis and invasion were detected
in hypoxic brain foci identified by SPAT and were elevated
compared with control brain. Immunohistochemistry, Western
blotting, and semi-quantitative RT-PCR showed that HIF-1·,
VEGF-A, and VEGFR2 (Flk-1) protein and mRNA expression
levels were significantly higher (P<0.05) in brain tumor tissues
compared to normal brain. Gelatin zymography and RT-PCR
demonstrated the upregulation of MMP-9 in tumor foci
compared with brain control. Together these results suggest
the critical role of hypoxia in driving tumor angiogenesis and
invasion through upregulation of target genes important for
these functions. Moreover this report validates our hypothesis
that a novel noninvasive technology (SPAT) developed in
our laboratory is suitable for detection of tumors, hypoxia,
and angiogenesis.
Introduction
The oxygen status of tumors plays a central role in tumor
pathophysiology and treatment. It is also a powerful prognostic
factor of disease-free survival. In addition, it appears to be
strongly associated with tumor growth, malignant progression,
and resistance to various therapies including radiotherapy,
photodynamic therapy, and chemotherapy (1). Prior studies
involving different techniques have measured one or more
parameters to define tumor hypoxia status. These include
magnetic resonance imaging to monitor vascular oxygenation
and blood flow (2), phosphorescence lifetime (quench) imaging
(3) to measure oxygen diffusion distances between micro-
vessels (4) and evaluate longitudinal tissue gradients of oxygen
(5), cryospectrophotometry to measure hemoglobin saturation
(6) single-photon emission computed tomography and positron-
emission tomography assays to measure perfusion and mark
hypoxic areas (7,8) and hypoxia markers to identify hypoxic
tumor regions (9). Unfortunately, none of these technologies
have produced a reliable measurement of tumor oxygen status
and tumor vascularity primarily because solid tumors are
usually characterized by a high degree of vascular and oxygen
tension heterogeneity. The technique used in this study,
spectroscopic photoacoustic tomography (SPAT) is based on
the measurement of laser-induced ultrasonic waves and has
contrast similar to that of pure optical imaging with spatial
resolution similar to that of pure ultrasonic imaging. Therefore
SPAT combines the advantages of two imaging modalities in
a single modality. The laser-induced ultrasonic signals from
biological samples depend on optical absorption in the sample
to reveal the structure of the tissue based on optical contrast
(10). The distribution of optical absorption in the object can be
reconstructed using photoacoustic signals which are detected
by highly sensitive piezoelectric devices. This technique used
for detection of oxygen saturation (SO2) is a noninvasive
imaging modality, based on the spectroscopic differences
between oxyhemoglobin (O2Hb) and deoxyhemoblobin (HHb)
(11). Since HHb and O2Hb are the dominant absorbers in the
rat brain region under study, with the reconstructed images at
multiple optical wavelengths, the contributions to the photo-
acoustic signals from HHb and O2Hb can be separated by
SPAT; thus spatial distribution of total hemoglobin (HbT) and
SO2 based on the estimated concentration of HHb and O2Hb
can be reconstructed. SPAT has the ability to image HbT and
SO2 with satisfactory penetration depth in the rat brain.
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Angiogenesis is an essential component for the growth of
tumors. It is an invasive process that requires lyses of the
extracellular matrix (ECM) plus proliferation and migration
of the endothelial cells (12). This complex process, regulated
by angiogenic factors and cytokines, is important for tumor
invasion (13). Vascular endothelial growth factor (VEGF), an
angiogenic mitogen secreted from various types of cells, is
involved in various physiological and pathological conditions,
including embryonic development, wound healing and solid
tumor growth. VEGF is known to stimulate the production of
various cytokines, growth factors, and proteinases, including
MMP-1, -3, and -9 (14). The expression of VEGF is regulated
by various physiological and pathological stimuli. Hypoxia
is a strong inducer of VEGF, and hypoxia-induced VEGF
expression determines the course of various disease conditions,
such as solid tumor growth (15). Moreover, hypoxia has been
shown to provide an important prognostic value in clinical
trials involving radiation and chemotherapy. It is usually
associated with adverse clinical outcomes and reduced patient
survival (16). Although tissue hypoxia usually occurs very
early in tumor development due to inadequate blood supply,
hypoxia remains a constant feature of these tumors even after
neovascularization (4). Several studies have shown that the
regulation of gene expression by oxygen is an important feature
of many biological processes, and hypoxia is a powerful
modulator of gene expression (17,18). The main regulator
which orchestrates the cellular responses to hypoxia is hypoxia-
inducible factor-1 (HIF-1), a heterodimeric transcription factor
composed of · and ß subunits critical for adaptive responses to
reduced oxygen (19). The HIF-1ß is thought to be expressed
constitutively and ubiquitously. HIF-1· is also constitutively
expressed, but is continuously degraded in the presence of
oxygen, by von Hippel Lindau tumor suppressor protein
leading to decreased HIF levels in normoxia and high levels
in hypoxia. Elevated HIF-1· expression, which could be an
indicator of the existence of hypoxia, has been reported in a
variety of human tumors and pre-neoplastic lesions (20,21).
The critical role of HIF-1· in tumor metastasis arises from the
fact that it is a potent activator of angiogenesis and invasion
through its upregulation of target genes important for these
functions. Hill and co-workers have found that exposure of
tumor-bearing rodents to cyclical, but not chronic, hypoxia
produces a significant increase in metastasis to the lungs (22).
Hypoxia was also found to be important in activation of extra-
cellular matrix degrading proteases (23).
Matrix metalloproteinases (MMPs) are structurally related
endopeptidases that play a role in proteolytic degradation of
structural components of extracellular matrix (24). They not
only facilitate breakdown of extracellular matrix, but also affect
early carcinogenesis, tumor development and growth. They
also play an important role in angiogenesis and mammary
gland involution (25). Among these enzymes, matrix metallo-
proteinase-9 (MMP-9) or gelatinase B plays an important
role in tumor invasion and metastasis because of its specificity
for type IV collagen. Recent studies have demonstrated that
the switch from vascular quiescence to angiogenesis involves
MMP-9/gelatinase B, which is upregulated in angiogenic islets
and tumors, releasing VEGF from an extracellular reservoir
(26). Prior observations have suggested that acidity in the
tumors can be caused by hypoxia-dependent and/or independent
pathways and MMP-9 was found to be induced by culturing
cells at acidic pH (27). Acidic pH was also found to increase
the expression of vascular endothelial growth factor in glioma
(28), and glioblastoma (29).
The present study provides an integrated approach to define
the oxygen status (hypoxia) of tumors by using SPAT and to
correlate hypoxia with the invasion process of a mammary
adenocarcinoma cell line ENU1564 inoculated intracranially
in a rat model. The mechanism of tumor invasion may apply
to tumor metastasis because metastasis mediators are involved
in both of these processes. Here we were able to successfully
obtain the brain oxygenation images, which clearly showed
tumor hypoxia. We also evaluated the expression of HIF-1·,
VEGF, VEGFR2 and MMP-9 protein and mRNA levels in the
hypoxic brain tumor foci. We demonstrated that the levels of
HIF-1·, VEGF, VEGFR2 proteins in brain tumor foci were
higher than the ones of normal brain tissues. Additionally,
MMP-9 enzymatic activity was higher in brain tumor foci. The
results were confirmed by semi-quantitative RT-PCR. The
regulation of proteins targeted in our study may be directly
correlated with hypoxia detected in the brain tumor foci by
SPAT. Such informations can be used not only as a prognostic
tool for tumor invasion but also as the basis for developing
and evaluating patient-specific treatment modalities for many
types of cancers. It should be possible to target hypoxic cells
by developing a gene therapy strategy that uses plasmids
containing suicide genes that are selectively expressed under
hypoxic conditions.
Materials and methods
Reagents. Chemicals, stains and solutions were obtained from
Sigma Chemical Co. (St. Louis, MO, USA) unless otherwise
indicated.
Cell culture. The ENU1564 tumor cell line used in this study
was originally developed in our laboratory and originated
from an N-ethyl-N nitrosourea-induced mammary adeno-
carcinoma in a female Berlin-Druckrey IV (BD-IV) rat.
This cell line is highly metastatic to brain and bone tissues
(30). Prior to inoculation, the cell line was maintained in
Dulbecco's modified Eagle's medium (DMEM) (Invitrogen,
Carlsbad, CA, USA), supplemented with 10% fetal bovine
serum (Invitrogen) and antibiotics (100 units/ml penicillin
and 100 μg/ml streptomycin).
Rat inoculation. Three-week old Sprague-Dawley (SD) rats
obtained from a colony maintained at Texas A&M University
were used. All animal experiments were done in accordance
with protocol approved by our Institutional Animal Care and
Use Committee (IACHC) and following National Institute
of Health (NIH) guidelines for animal welfare. Stereotaxic
implantation of tumor cells was performed under full anesthesia
using a mixture of Ketamine (Ketant, Fact Dodge Animal
Health) and xylazin (Ane Sed, Lloud Laboratories). A stereo-
taxic frame was used to stabilize the animal's head. The hair
on the rat's head was gently removed with hair-removal lotion.
The site of inoculation was marked at a point 2.5 mm lateral
and 1 mm anterior to the bregma. This point was chosen
because of its location directly above the caudate nucleus,
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which has been shown to be a highly reliable intracranial site
for tumor engraftment. The cells were inoculated intracranially
at 3 mm depth from the cranial surface. A Hamilton syringe
was used to inoculate 3 μl tumor cell suspensions (5x106 cells)
over 5 min period. Three weeks post inoculation the animals
were subjected to SPAT evaluation. After the SPAT evaluation
the animals were euthanatized with Pentobarbital (150 mg/kg,
intraperitoneal injection) and the brain tumors were used
for Western blot analysis, gelatin zymography, and RT-PCR
experiments.
Tissue processing and tumor collection. For Western blot
analysis, gelatin zymography, and RT-PCR, brains were
immediately removed after death and placed on powdered
dry ice. Brains from rats inoculated intracranially with tumor
cells (n=3) and from age-matched non-inoculated control rats
(n=3) were used. Samples were kept at -80˚C. Brain tumors
were collected from frozen brain sections. The half of the
brain that was frozen in powdered dry ice was sectioned using
a cryostat (Bright Instrument Company, Ltd., Huntington,
UK) in 12 μm sections and placed on slides. Every fifth slide
was stained with 0.1% thionine solution. Thionine solution
stained the cell nuclei and displayed the tumor foci under
light microscopy. The information was used to dissect the
tumor foci, on frozen brain tissue sections. For immuno-
histochemistry, brain tumor-bearing (n=3) and tumor-free
(n=3) SD rats were perfused with 4% paraformaldehyde
(PFA) solution (Electron Microscopy Science, PA, USA) in
PBS (phosphate buffer saline) using a peristaltic pump. Brains
were then removed and post-fixed in 4% PFA in PBS for 24 h,
after which the brains were further processed.
Immunohistochemistry. Five-micron paraffin-embedded
sections were used for immunohistochemical study. After
deparaffinization the sections were subjected to an antigen
retrieval protocol by heating them in 10 mM citrate buffer
(pH 6.0) for 10 min. Potential non-specific binding sites were
blocked with 5% normal goat or rabbit serum in PBS. After
blocking, the sections were incubated for 1 h to overnight
with primary antibody. For activated microglial cells we
used a mouse anti-rat CD68: biotin from Serotec Company
(Hidlington, Oxford, UK). Mouse anti-glial fibrillary acidic
protein (GFAP) was purchased from Chemicon International
(Temecula, CA, USA). The other primary antibodies, MMP-9,
VEGF-A, VEGFR2, and HIF-1· were purchased from Santa
Cruz Bitotech (Santa Cruz, CA) and a 1:50 dilution was used.
Following primary antibody reaction, sections were washed
and incubated with either biotin-conjugated anti-rabbit or
anti-goat IgG (Vector Laboratories, Burlingame, CA, USA).
A Vector-ABC streptavidin-peroxidase kit with a benzidine
substrate for color and streptavidin-phosphatase kit (KPL,
MD, USA) with a HistoMark Red substrate (KPL) were used
for color development. Counter-staining was done with diluted
hematoxylin. Sections that were not incubated with primary
antibody served as negative control. To visualize the tumor
foci on paraffin-embedded sections, hematoxylin and eosin
staining was performed.
Western blot analysis. After microscopic dissection of frozen
brain specimens, the tissues was homogenized in lyses buffer
containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM
CaCl2, 1 mM MgCl2, 0.1% Triton X-100. The lysates were
cleared by centrifugation at 13,000 x g at 4˚C for 30 min, and
the supernatant kept frozen at 80˚C. The protein content of
the lysates was determined using Bradford Assay (Bio-Rad),
with bovine serum albumin as the standard. Proteins (15-30 μg)
were separated by 9-12% SDS polyacrylamide gel electro-
phoresis (SDS-PAGE) and transferred to nitrocellulose
membranes (Schleicher and Schuell, Keene, NH, USA).
Membranes were incubated 1 h in blocking buffer (20 mM
Tris-HCl buffered saline containing 5% nonfat milk powder
and 0.1% Tween-20) at room temperature and then probed
with appropriate antibodies in blocking buffer or blocking
buffer including 5% bovine serum albumin instead of 5%
nonfat milk overnight at 4˚C. Blots were incubated at 4˚C
overnight with anti-MMP-9 (1:200); anti-HIF-1· (1:200), anti-
VEGF-A (1:200), anti-VEGFR2 (Flk-1) (1:100), (all antibodies
from Santa Cruz Bitotech), washed extensively and then
incubated for 1 h with a 1:5000 dilution of secondary antibody.
Peroxidase labeled anti-rabbit and anti-mouse secondary anti-
body were purchased from Kirkegaard and Perry Laboratories
(MD, USA). Monoclonal mouse IgG antibody against ß-actin
was purchased from Sigma Chemical Co. After additional
washes, the blots were incubated with chemiluminescent
substrate, according to directions in the kit (Super Signal
West Pico, Pierce, Rockford, IL).
Gelatin zymography. Gelatinolytic activities were analyzed
by gelatin zymography as previously described (31). Protein
lysates were incubated at 37˚C for 30 min in SDS sample
buffer without reducing agent and then subjected to SDS-
PAGE in 10% (wt/vol) polyacrylamide gels containing 0.1%
(wt/vol) gelatin. The gels were washed twice for 30 min in
2.5% (vol/vol) Triton X-100 at room temperature and then
incubated for 24 h in substrate reaction buffer [50 mM Tris-
HCl (pH 7.5), 100 mM NaCl, 10 mM CaCl2, 0.002% NaN3]
at 37˚C. The gels were then stained with Coomassie Brilliant
Blue R250 in 10% (vol/vol) acetic acid and 30% (vol/vol)
methanol for 1 h and destained briefly in the same solution
without dye. Proteolytic activities were detected as clear bands
indicating the lyses of the substrate.
Total RNA extraction and semi-quantitative RT-PCR. Total
RNA was extracted from frozen specimens using an SV RNA
extraction kit (Promega) following the manufacturer's
directions. RNA was quantified by absorbance at 260 nm.
Using a SuperScript III First Strand Synthesis System
(Invitrogen), 100 ng of total RNA was amplified by reverse
transcription polymerase chain reaction (RT-PCR) and the
cDNAs were amplified in a 25-μl reaction. PCR primers
were as follows: MMP-9 primers (forward, 5'-CCCCACTTA
CTTTGGAAACGC-3'; reverse, 5'-ACCCACGACGATA
CAGATGCTG-3') (32); HIF-1· primers (forward, 5'-
GTCGGACAGCCTCACCAAACAGAGC-3'; reverse, 5'-
GTTAACTTGATCCAAAGCTCTGAG-3') (33); VEGF
primers (forward, 5'-GACCCTGGTGGACATCTTCCA
GGA-3'; reverse, 5'-GGTGAGAGGTCTAGTTCCCGA-3')
(14); ß-actin primers (forward, 5'-ATGTACGTAAGCC
AGGC-3'; reverse, 5'-AAGGAACTGGAAAAGAGC-3')
(32).
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The expected size for MMP-9 PCR product was 686 base
pairs (bp). PCR condition for MMP-9 was carried out with an
initial denaturation of 94˚C for 2 min, followed by 30 cycles
at a denaturation of 94˚C for 1 min, annealing at 59.1˚C for
30 sec and extension at 72˚C for 1 min. A final extension of
5 min at 72˚C was carried out. For HIF-1·, 25 cycles were
carried out with 30 sec at 95˚C, 1 min at 55˚C and 2.5 min at
72˚C. A final extension of 7 min at 72˚C was carried out. The
PCR product size for HIF-1· was 487 bp. For VEGF, one set
of rat primers, which amplified 3 splicing variants of a rat
VEGF mRNA (VEGF120, VEGF164 and VEGF188) was used.
The PCR profile consisted of initial denaturation at 94˚C for
7 min, followed by 35 cycles of denaturation at 94˚C for 30 sec,
annealing at 58˚C for 30 sec, extension at 72˚C for 90 sec,
and extension at 72˚C for 7 min. The expected length of the
PCR products was 330 bp for VEGF120, 462 bp for VEGF164,
and 514 bp for VEGF188. To demonstrate the integrity of
the RNA samples used in the RT-PCR reactions, parallel
amplifications with oligonucleotide primers for mouse ß-actin
were performed. The expected size for ß-actin PCR product
was 403 bp. PCR fragments were analyzed on 1.5% agarose
gels stained with ethidium bromide.
Experimental setup of SPAT. Three weeks after intracranial
inoculation, experimental rats had developed neurological
signs such as ataxia and head tilt. At that time the experimental
rats were imaged using SPAT. Four successful SPAT images
showing tumor hypoxia in the SD rat brains were achieved as
described in Fig. 1. Three rats of similar age, inoculated
intracranially with 3 μl of DMEM medium, were used as
controls. Briefly, each animal was anesthetized using Ketamine
(87 mg/kg, intramuscular injection) and the hair from the top
of the head was removed. A tunable Ti:Sa nanosecond pulse
laser (LT-2211A, Lotis T II, Minsk, Belarus) pumped by an
Nd:YAG laser was employed to provide laser pulses with a
pulse repetition rate of 10 Hz. The laser beam was expanded
by a concave lens and homogenized by a light diffuser and then
delivered to the animals head (Fig. 1). The incident energy
density of the laser beam on the surface of the rat head was
controlled at ~20 mJ/cm2 (within the ANSI standard). The
energy of each single laser pulse was monitored using a
photodiode (PD) and recorded. The photoacoustic signals
were normalized by the recorded PD signals to reduce the
effect of laser-energy fluctuation. A 2.25-MHz ultrasonic
transducer (V323, Panametrics) was used to detect the laser-
induced acoustic signals. The active area diameter was 6 mm
and it had a nominal band-width of 66%. A computer
controlled step motor drove the 2.25 MHz transducer to
circularly scan the head of the SD rat at a depth of ~3 mm
below the skin surface, at a radius of 4.5 cm, and with a step
size of 3 degree. During the SPAT scan, the rat was fixed by
a homemade restraint mount. A water tank was used that had
a sealed opening in the bottom such that the rat's head could
protrude along the bottom of the water surface and stay dry
(Fig. 1). The hole was sealed with a piece of polyethylene
membrane. The rat head surface was covered with a thin layer
of ultrasonic coupling gel. Health status, pulse rate and the
global arterial blood oxygenation of the rat were monitored
throughout the entire experiment using a pulse oximeter. The
detected photoacoustic signals were amplified, digitized by
an oscilloscope, and then transferred to a computer. Four
wavelengths (764, 784, 804, and 824 nm) were changed at
each scanning step. After a single full-view scan, the images
at different wavelengths were reconstructed based on a
modified back projection algorithm (34). Then the
reconstructed images at the four different wavelengths were
used to estimate the spatial distribution of the concentration of
HHb and O2Hb using a standard linear least-squares method.
Statistical analysis. Quantification of the Western blot analysis,
gelatin zymography, and semi-quantitative RT-PCR bands
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Figure 1. Experimental setup for the in vivo SPAT of an SD rat head.
Figure 2. Estimated brain blood oxygen saturation image from noninvasive
in vivo spectroscopic photoacoustic tomography (SPAT) of an SD rat brain
at three weeks post inoculation with ENU1564 cells. The circle indicates the
position of the tumor. (a), SPAT image of a tumor-free rat brain, which shows
well-defined symmetrical vascular architecture in both cerebral hemispheres.
(b), SPAT image of the rat brain inoculated intracranially with ENU1564 cells
and reveals the vascular architecture associated with the tumor, which is
different from that of a normal brain SPAT image. (c), Open-skull photograph
of the rat brain after SPAT experiment shows the tumor position in the cerebral
hemisphere. (d), Estimated brain blood oxygen saturation (SO2) image.
45-54  6/12/06  18:48  Page 48
density was performed on a Macintosh computer using the
public domain NIH Image program (developed at the US
National Institutes of Health and available on the internet at
http://rsb.info.nih.gov/nih-image). Data were presented as
mean ± SD, and statistical comparisons were made using
Student's t-test. A P-value of <0.05 was considered statistically
significant.
Results
Spectroscopic photoacoustic tomography (SPAT) imaging of
the SD rat brain tumor three weeks after inoculation with
ENU1564 cell line. SPAT images from four tumor-bearing SD
rat brains showed hypoxia. The most representative SPAT
image of brain tumor hypoxia is showed in Fig. 2. None of
the SPAT images of tumor-free SD rat control brains showed
hypoxia. Differences in brain vasculature between a tumor-
free SD rat brain (Fig. 2a) and a tumor-bearing SD rat brain
(Fig. 2b) are illustrated. Compared with the tumor-bearing rat
brain, SPAT images of the tumor-free brain showed a well-
defined symmetrical vascular architecture in both cerebral
hemispheres. In Fig. 2c, an open-skull photograph of the rat
brain taken right after the SPAT experiment, showed a tumor in
the right hemisphere. The position of the tumor corresponded
with the location of the tortuous irregular distorted vessels
shown in Fig. 2c. The SO2 image of the rat brain with intra-
cranial inoculation of ENU1564 cells is represented in Fig. 2d.
The SO2 value is lower in the brain tumor area compared to
the rest of the brain. Fig. 3 shows the H&E staining of the
tumor foci inside the rat brain imaged by SPAT. The diameter
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Figure 3. Histology (H&E staining) of the tumor foci inside the SD rat brain at various microscopic magnifications (a-c). The tumor is observed as a
basophilic, hypercellular area composed of neoplastic epithelial cells. (a), x4; (b), x20; and (c), x40.
Figure 4. Activation of astrocytes and microglial cells around and inside the
brain tumor foci. (a), Activation of astrocytes (brown color) around tumor foci
(immunohistochemical staining for GFAP) (x10). No reactivity of astrocytes
was observed inside the brain tumor foci. (b), Active microglial cells around
and inside the tumor foci, which is denoted by brown color (x20). Arrows
indicate the tumor foci.
Figure 5. Localization of HIF-1· in hypoxic tumor foci. Immunohistochemical
staining (red) of HIF-1· protein in the tumor foci revealed positivity within
neoplastic cell cytoplasm and nucleus (a and b) (x10). Arrows indicate the
neoplastic cells within tumor foci which stain positive for HIF-1· in both
cytoplasm and nucleus. Positive control is represented in (c) and revealed
cytoplasmic HIF-1· staining (x10). (d), Higher magnification view of the
neurons in (c). Note the absence of nuclear HIF-1· staining in neurons. Arrow
indicates cytoplasmic HIF-1· staining of the neurons. Sections exposed to a
negative control antibody showed no staining reactions (e). (x20).
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of the tumor area was around 2.5 mm. Histological examination
of H&E-stained brain sections revealed increased mitosis in
the tumor cells which demonstrated that ENU1564 cell line
was highly invasive.
Histological evaluation of the neoplastic foci. Three weeks
after intracranial inoculation with ENU1564 cells the rats were
euthanatized. Histological evaluation of the brain revealed
intracranial neoplasia affecting most frequently the caudate
nuclei. Morphologically, clusters of epithelial neoplastic cells
resembling the cultured cell line were observed. The tumor
foci were devoid of fibrous stroma, and necrosis. Marked
gliosis consisting of astrocytes (Fig. 4a) and microglial cells
(Fig. 4b) was observed around and inside the neoplastic foci.
The data represent three separate experiments with similar
results.
Immunolocalization of HIF-1· protein in the tumor foci. Tumor
cells respond to low-oxygen conditions via the stabilization
and activation of hypoxia-inducible factor-1· (HIF-1·), a
transcription factor critical for adaptive responses to reduced
oxygen. Immunohistochemistry for HIF-1· was performed in
order to demonstrate that hypoxia was localized within the
tumor foci. IHC results showed cytoplasmic and nuclear
immunolabeling with moderate intensity of the neoplastic cells
within the brain tumor foci (Fig. 5a and b). Positive control,
represented in Fig. 5c and d, showed that some neurons also
had moderate staining in the cytoplasm but not in the nucleus.
A negative control is represented in Fig. 5e.
Immunohistochemistry for vascular endothelial growth factor
(VEGF-A) and vascular endothelial growth factor receptor
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Figure 6. Localization of VEGFR2 (Flk-1) in tumor foci. (a), VEGFR2 labeling
of the tumor foci (x10). (b), Higher magnification view of tumor cells showing
cytoplasmic and membrane VEFGR2 staining (x20). (c), No staining was
observed in the negative control. (d), Endothelial cells lining a blood vessel
adjacent to the tumor foci also stain positive for VEGFR2 (x40).
Figure 7. Immunolocalization of VEGF-A in brain tumor foci and surrounding
glial cells. (a), Low-power (x4) view of VEGF-A-positive tumor foci. (b),
Higher magnification view of tumor cells showing cytoplasmic VEGF-A
staining (x40). (c), Positive control (x20) showing VEGF-A labeling of
some glial cells. (d), No staining was observed in the negative control (x20).
Figure 8. Localization of MMP-9 in the brain metastatic foci. (a), Immunohistochemical staining (brown) of MMP-9 protein in the tumor foci (x20). Note moderate
staining in the neurons. (b), Higher magnification view (x40) of the tumor cells showing cytoplasmic MMP-9 staining. Arrows indicate the tumor foci. Negative
control for MMP-9 is shown in (c).
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VEGFR2 (Flk-1). Further analysis was focused on the VEGF-A
and VEGF receptor, VEGFR2 (Flk-1). Immunohistochemical
staining for VEGF and VEGFR2 (Flk-1) was performed in
order to characterize the expression of these proteins within
tumor foci. Previous studies showed that HIF-1· is the major
transcription factor responsible for induction of VEGF pro-
duction and secretion. IHC staining for VEGFR2 (Flk-1)
showed immunolabeling of the neoplastic cells (Fig. 6a and b).
Endothelial cells lining blood vessels also show positivity for
VEGFR2 (Fig. 6d). No staining was observed in the negative
controls (Fig. 6c). VEGF staining was observed in the cyto-
plasm of the neoplastic cells (Fig. 7a and b). Positive control
revealed that some glial cells are also labeled for VEGF-A
(Fig. 7c). No staining was observed in the negative controls
(Fig. 7d).
Immunohistochemistry for MMP-9 in brain tumor foci. Given
the fact that in addition to the upregulation of VEGF hypoxia
may be a factor in activation of extracellular matrix degrading
proteases we evaluated IHC for MMP-9. Immunohistochemical
staining for MMP-9 showed immunolabeling with moderate
intensity in the neoplastic cell cytoplasm and faint staining
of the glial cells (Fig. 8a and b). Negative control slide is
represented in Fig. 8c.
Increased expression of HIF-1·, VEGF-A and VEGFR2 (Flk-1)
proteins in brain tumor foci. To confirm the IHC results on
HIF-1·, VEGF-A and VEGFR2 (Flk-1) we extracted proteins
from brain tumor foci and control brain. Evaluation of protein
expression by Western blotting revealed that all three proteins
were significantly higher in tumor foci compared with control
tissue from brains of age-matched-non-inoculated rats (Fig. 9a).
Given that HIF-1· is the major transcription factor responsible
for induction of VEGF production and secretion it was
important to determine if VEGF was also upregulate in neo-
plastic cells. VEGFR2 (Flk-1) protein, which is a VEGF
receptor was also found to be significantly upregulated in
tumor foci. Quantitative analysis (Fig. 9b-d) was determined
by densitometry.
Increased MMP-9 activity in brain tumor foci. To confirm
the IHC results on MMP-9 protein expression and to evaluate
the enzymatic activity of MMP-9 in the brain tumor foci
gelatin zymography was performed. The results revealed an
increase in enzymatic activity of MMP-9 in brain tumor foci
compared with control brain (Fig. 10A). Quantitative analysis
determined by densitometry revealed an increase in pro- and
active forms of MMP-9. Fig. 10B represents the quantitative
analysis of MMP-9 determined by densitometry of the active
band (b).
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Figure 9. Increased expression of HIF-1·, VEGF-A, and VEGFR2 (Flk-1)
proteins in neoplastic cells. (a), Evaluation of protein expression by Western
blotting. The membranes were stripped and re-probed with ß-actin antibody to
confirm equal loading. (b-d), Densitometric analysis of HIF-1·, VEGF, and
VEGFR2 (Flk-1) protein expression in tumor cells showed significant
increases compared with control brain. The results represent the mean ±
standard deviation for three control and three tumor samples. Asterisks indicate
statistically significant differences (P<0.05).
Figure 10. MMP-9 enzymatic activity in tumor foci compared with brain
control. (A), Increased MMP-9 enzymatic activity in the tumor foci. The
double band at 97 kDa corresponded to the latent form (a) (proenzyme) and
active form (b) of MMP-9. (B), Quantitative analysis of MMP-9 was
determined by densitometry of the active band (b). Data are represented as
mean ± standard deviation, for three independent experiments and asterisks
indicate statistically significant differences (P<0.05).
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Increased expression of HIF-1·, VEGF, and MMP-9 mRNA
in the SD rat brain tumor cells. To confirm the IHC and WB
results on HIF-1·, VEGF, and MMP-9 protein expression, we
prepared cDNA from dissected tumor sample and performed
semi-quantitative RT-PCR analysis. Although this technique
is semi-quantitative, our results indicate that there were higher
levels of HIF-1·, VEGF, and MMP-9 mRNA in brain tumor
foci than in normal brain tissues from age-matched non-
inoculated rats (Fig. 11a). For VEGF, the RT-PCR from brain
control and brain tumor tissues demonstrated three alternative
splicing variants: 330, 462 and 514 bp DNA fragments,
corresponding to VEGF120, VEGF164 and VEGF188. VEGF188
isoform was greater than those of VEGF120, and VEGF164.
Discussion
In the present study we were able to detect tumor hypoxia in a
rat intracranially implanted with a malignant mammary tumor
cells by measuring the brain tumor SO2 through the intact
skin and skull using a novel noninvasive spectroscopic photo-
acoustic tomography technology. Validation of this technology
is supported by our molecular biology findings. Detection
and measurement of the level of brain blood oxygenation can
be used to monitor tumor hypoxia, an important parameter
of tumor pathogenesis. We found increased expression of
HIF-1·, VEGF, VEGFR2, and MMP-9 in the brain tumor foci
suggesting that these molecules may be induced by tumor
hypoxia and may be directly involved in the invasion of the
tumor cells into the brain parenchyma. It is known that hypoxia
modulates invasion-associated cytokines, such as matrix
metalloproteinase, and their inhibitors in tumor and normal
cells (35).
Previously, in our laboratory Mendes et al using an in vivo
animal model, showed that MMP-2, -3, and -9 are involved
in mammary adenocarcinoma metastasis to the brain (32).
The animal model used in those studies was developed in
our laboratory (30). The syngeneic animals inoculated with
ENU1564 cells via the left ventricle consistently produced
brain metastasis. For our study we chose to inoculate the
tumor cells (ENU1564) intracranially into the rat forebrain
since we were mainly interested in locating tumor implant
and detecting tumor hypoxia inside the brain using SPAT, as
an assessment of this new technology. The mechanism of
tumor invasion resulting from the tumor implant may apply for
tumor metastasis because metastasis mediators are involved in
both of these processes. Our results showed the presence of
tumor hypoxia in the rat brain three weeks post-inoculation.
We used non-inoculated brains of age-matched rats as
controls, assuming that differences in HIF-·, VEGF, VEGFR2,
and MMP-9 would be attributable to the presence of tumors.
Our results showed the increased expression of HIF-1· at
both protein and mRNA levels, which is an indicator of the
existence of hypoxia in the brain tumor foci. These results
were in accordance with previous studies, which showed
elevated HIF-1· expression in a variety of human tumors and
pre-neoplastic lesions (20,21). Immunohistochemistry revealed
the localization of HIF-1· protein in the cytoplasm and nucleus
of neoplastic cells. Localization of the HIF-1· in the nucleus
is an indication of protein stability in hypoxic conditions which
is the major transcription factor responsible for induction of
VEGF production but can also activate different genes by
binding to their promoter sequences. Hypoxia-induced
expression of VEGF has been well established in various
types of non-neoplastic and neoplastic cells (36,37).
Considering that previous studies showed that matrix
metalloproteinases are important in tumor invasion and meta-
stasis (25,27,32), we focused on MMP-9 expression in brain
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Figure 11. Increased expression of HIF-1·, VEGF, and MMP-9 mRNA in the
rat neoplastic brain foci. (a), Semi-quantitative RT-PCR was used to detect
HIF-1·, VEGF, and MMP-9 and ß-actin in total RNAs from normal brain and
neoplastic brain foci. ß-actin was used as an internal control. For VEGF three
alternative splicing variants were identified. A 330-bp product, which is
identical to that of the alternative splicing VEGF120 isoform. A second 462 bp
product, corresponding to the VEGF164 isoform, and a third 514-bp product,
corresponding to the VEGF188 isoform were also detected. VEGF188 isoform
expression was greater than those of VEGF164 and VEGF120. (b-d), Quantitative
analysis of VEGF, MMP-9, and HIF-1 was determined by densitometry. The
results are mean ± standard deviation from three controls and three tumor
samples. *P<0.05.
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tumor foci. Evidence suggested that MMP-9 was associated
with intratumoral angiogenesis and with the metastatic process
of breast cancer. Our results showed an increased expression
of protein and mRNA level of MMP-9 in the brain tumor foci
compared with non-inoculated control brain. Gelatin zymo-
graphy confirmed an increase in gelatinase activity of MMP-9
in tumor brain foci. These results are in accordance with the
previous reports correlating MMP-9 activity with invasive
and metastatic behavior (38). The upregulation of MMP-9 in
brain tumor foci might be directly related to the presence of
hypoxia in the brain tumor foci. Interestingly, previous studies
showed that besides the upregulation of HIF-1· in hypoxia
other transcription factors such as c-jun/AP-1 (activator
protein) are also upregulated (16). Elevation of AP-1 level in
hypoxic cells can be one possible mechanism of the MMP-9
upregulation since the promoter of MMP-9 has a site for
binding of AP-1 complex.
We analyzed the expression level of protein and mRNA of
VEGF and VEGFR2 in brain tumor foci since the mechanism
involved in tumor invasion may include hypoxic regulation
of cytokine release, and growth factor receptor. In this study,
comparison of tumor xenograft and control brains demonstrated
that the brain tumor upregulated the expression of VEGF
mRNA and protein, which arose as three alternative splicing
variants VEGF120, VEGF164 and VEGF188. The genetic studies
showed that the VEGF120 isoform alone is able to initiate, but
not complete, the angiogenic programme (39). Although the
target of VEGF was thought to be restricted to endothelial
cells, more and more evidence has indicated that non-
endothelial cells can be VEGF targets by expressing VEGF
receptors (13). The production and upregulation of VEGF in
brain tumor foci is important for tumor vascularization and
may confer proteolytic activity to the neoplastic cells by
induction of MMP-9. Our results showed that VEGFR2
protein was up-regulated in brain tumor foci compared with
brain control (Fig. 9a). VEGFR2 is considered to be the main
mitogenic signaling receptor for VEGF (19). Skobe et al
demonstrated the role of VEGFR2 for the invasive growth of
skin squamous cell carcinoma cells (40). Recently, Noda et al
demonstrated the hypoxic upregulation of VEGF and
VEGFR2 and their involvement in hypoxia-induced MT1-
MMP expression in retinal glial cells. This upregulation was
abrogated in the presence of SU1498, a selective inhibitor of
VEGFR2 or by using a neutralizing anti-VEGF antibody (41).
The upregulation of VEGF, VEGFR2 and MMP-9 might be a
consequence of decreased tissue oxygen concentration which
leads to up-regulation of HIF-1·. Direct or indirect interaction
of both transcription factors c-jun/AP-1 and HIF-1· is a
suggested mechanism for regulation of at least some of the
known hypoxia-inducible genes. Upregulation of all these
factors under hypoxic conditions enables the cells to survive
reduced tissue oxygen concentration by promoting angio-
genesis and tumor metastasis.
Because evidence suggested that astrocytes and/or glial
cells may have a role in tumor invasion (32) we analyzed how
these cell types reacted in a tumor-bearing brain. Prior studies
showed that astrocytes are thought to play a role in MMP-9
activation and expression (42). Immunohistochemical staining
using GFAP antibody (glial fibrillary acidic protein) demon-
strated marked astrocytic proliferation around neoplastic foci
(Fig. 4a). Astrocytes, which populated brain parenchyma,
synthesized a host of biological proteins including TGF-ß,
TNF-·, interferon-Á, IL-1, IL-3, IL-6, and other cytokines
which may be very important for tumor invasion (42). Studies
showed that brain metastatic and parental cancer cell line co-
cultured with astrocytes or cell culture supernatants of astro-
cytes, exhibited increased adherence to astrocytes and grew
better in response to the conditioned media (43). Microglial
reactivity around and inside the tumor foci was also confirmed
(Fig. 4b). The presence of reactive glial cells around tumor
cells in the brain suggests the possibility that these cell types
could be interacting. Further studies are needed in order to
characterize the role of those cells in tumor progression into
the brain parenchyma.
Tumor oxygen status appears to be strongly associated
with tumor growth, malignant progression, and resistance to
various therapies (1). Among the genes upregulated in hypoxia,
those involved in angiogenesis and degradation of extracellular
matrix appears to be very important in malignant progression
(12). Tumor oxygen status may also be important in the
assessment of the efficacy of agents classified as antiangiogenic
compounds, which target tumor vasculature (1). Therapy with
antiangiogenic compounds may be more important than those
which cause direct cytotoxicity to malignant cells. Detection
of tumor hypoxia can be used as a prognostic tool and for
developing and evaluating patient specific treatment modalities
for many types of cancer. In 2004, Evans et al showed that the
presence of more severe hypoxia in glial tumors correlated with
a more aggressive clinical behavior (44). Also, the presence of
hypoxia in locally cured high-grade sarcomas was associated
with a greater likelihood of metastasis and death (45).
This study shows that SPAT would be an important tool
for noninvasive detection of intracranial tumors. Moreover,
SPAT would be useful for monitoring the development of
hypoxia, which may have an important role in determining
the timing and type of therapy. SPAT is also a promising
imaging modality for the study of the functional and structural
organization of the brain. In combination with reporter genes,
SPAT offers promise for imaging pathological processes at
molecular levels, and monitoring the delivery of vectors to
specific cells by gene therapy.
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